medigraphic.com
ISSN 2500-7106 (Electronic)
ISSN 0123-2576 (Print)
Medicina & Laboratorio

2023, Number 1

<< Back Next >>

Medicina & Laboratorio 2023; 27 (1)

Safety of esophageal endoscopy and biopsy in a patient with eosinophilic esophagitis and Von Willebrand disease

Herrera-Hoyos S, Ortiz-Gualdrón CA

Language: Spanish
References: 13
Page: 39-44
PDF size: 88.99 Kb.


ABSTRACT

Eosinophilic esophagitis (EoE) is a disease caused by an immune response against food antigens in contact with the esophageal mucosa; alternatively, Von Willebrand disease (VWD) is the most common inherited bleeding disorder in humans. The central characteristic of all types of VWD is the presence of reduced amounts or abnormal forms of VWF in the bloodstream. Since no previous cases of VWD type 2A associated to EoE have been reported, this clinical case is described with the main objective to present the coincidental finding of these two pathologies, the safety of the evaluation by upper gastrointestinal endoscopy, and the prognosis of possible complications.


REFERENCES

  1. Corder SR, Weston BW, Dellon ES. Rare cooccurrenceof eosinophilic esophagitis andtype 2B von Willebrand disease: Implicationsfor endoscopic surveillance and esophageal dilation.ACG Case Rep J 2019;6:e00069. https://doi.org/10.14309/crj.0000000000000069.

  2. Muñoz-Ortiz É, Juliao-Baños F. Esofagitis eosinofílica:estado actual. Iatreia 2012;26:54-66.

  3. Tomaszewski M, Bienz M, Kherad O, RestelliniS, Laflèche T, Barkun A, et al. Low endoscopybleeding risk in patients with congenitalbleeding disorders. Haemophilia 2019;25:289-295. https://doi.org/10.1111/hae.13691.

  4. Davis A, Walsh M, McCarthy P, Brown G, RobertsS, Tran H, et al. Tranexamic acid withoutprophylactic factor replacement for preventionof bleeding in hereditary bleeding disorderpatients undergoing endoscopy: a pilot study.Haemophilia 2013;19:583-589. https://doi.org/10.1111/hae.12146.

  5. Sabih A, Babiker HM. Von Willebrand disease.StatPearls. Treasure Island (FL): StatPearls Publishing;2022. Acceso 11 de agosto de 2022.Disponible en https://www.ncbi.nlm.nih.gov/books/NBK459222/.

  6. Goodeve A, James P, Adam MP, Everman DB,Mirzaa GM, et al. von Willebrand Disease. GeneReviews®. Seattle (WA): University of Washington,Seattle; 2009. Acceso 12 de agosto de2022. Disponible en https://www.ncbi.nlm.nih.gov/books/NBK7014/.

  7. Doruelo AL, Haberichter SL, ChristophersonPA, Boggio LN, Gupta S, Lentz SR, et al. Clinicaland laboratory phenotype variability in type2M von Willebrand disease. J Thromb Haemost2017;15:1559-1566. https://doi.org/10.1111/jth.13742.

  8. Tosetto A, Castaman G. How I treat type 2 variantforms of von Willebrand disease. Blood2015;125:907-914. https://doi.org/10.1182/blood-2014-08-551960.

  9. Khan S, Guo X, Liu T, Iqbal M, Jiang K, ZhuL, et al. An update on eosinophilic esophagitis:Etiological factors, coexisting diseases, andcomplications. Digestion 2021;102:342-356.https://doi.org/10.1159/000508191.

  10. Connell NT, Flood VH, Brignardello-PetersenR, Abdul-Kadir R, Arapshian A, Couper S, etal. ASH ISTH NHF WFH 2021 guidelines on themanagement of von Willebrand disease. BloodAdv 2021;5:301-325. https://doi.org/10.1182/bloodadvances.2020003264.

  11. Weyand AC, Flood VH. Von Willebrand disease:Current status of diagnosis and management.Hematol Oncol Clin North Am2021;35:1085-1101. https://doi.org/10.1016/j.hoc.2021.07.004.

  12. Uchida AM, Ro G, Garber JJ, Peterson KA,Round JL. Models and tools for investigatingeosinophilic esophagitis at the bench.Front Immunol 2022;13:943518. https://doi.org/10.3389/fimmu.2022.943518.

  13. Tovar-Sánchez C, Salazar-Reviakina A,Rumbo-Romero JA, Sierra-Bretón MM,Madariaga-Perpiñán I, Zarante-MontoyaI. ¿Qué avances recientes hay en el entendimiento,diagnóstico y tratamiento de la enfermedadde Von Willebrand?: una revisión dela literatura. Univ Med 2020;61:15. https://doi.org/10.11144/Javeriana.umed61-2.vonw




2020     |     www.medigraphic.com